NLRP3 inflammasome
The NLRP3 inflammasome is a multiprotein complex of the innate immune system, assembled around the sensor protein NOD-like receptor family pyrin domain containing 3 (NLRP3, also called cryopyrin).
The NLRP3 inflammasome is a multiprotein complex of the innate immune system, assembled around the sensor protein NOD-like receptor family pyrin domain containing 3 (NLRP3, also called cryopyrin). Together with the adaptor protein ASC and the effector protease caspase-1, it forms a cytosolic signaling platform that converts diverse danger signals into an inflammatory response. Its assembly conventionally requires two steps: a priming signal, typically delivered through toll-like receptor 4 and NF-κB–dependent transcription, which raises NLRP3 and pro-interleukin-1β levels, and an activation signal that triggers oligomerization. Once assembled, the complex activates caspase-1, which cleaves Pro-IL-1β and pro-IL-18 into the mature cytokines interleukin-1β and interleukin-18, and cleaves Gasdermin D to release a pore-forming fragment that drives pyroptotic cell death and cytokine release.
NLRP3 is unusual among innate immune sensors in responding to a broad and chemically unrelated set of stimuli rather than a single ligand, integrating cues such as reactive oxygen species, mitochondrial dysfunction and mitochondrial DNA release, lysosomal destabilization, potassium efflux, and crystalline or aggregated material including amyloid beta. This positions it at the center of sterile inflammation, and it has been implicated in type 2 diabetes and diabetic complications such as diabetic kidney disease and diabetic cognitive impairment, obesity and metabolic dysfunction–associated steatotic liver disease, neurodegenerative and neuroinflammatory conditions including Alzheimer's disease and Parkinson's disease, traumatic brain injury, postoperative cognitive dysfunction, osteoporosis, and fibrotic and ischemic tissue injury. Regulatory inputs studied alongside it include TXNIP, the antioxidant transcription factor Nrf2, Sirt1 signaling, mitophagy, and cross-talk with the cGAS-STING pathway. Pharmacologically, NLRP3 is an actively pursued anti-inflammatory target: the selective small-molecule inhibitor MCC950 is a standard experimental tool, and polyphenols and other natural products such as quercetin and gallic acid, mesenchymal stem cell– and extracellular vesicle–based approaches, nanoparticle formulations, and non-pharmacological interventions including electroacupuncture have all been examined for their ability to suppress inflammasome activation.
Where the papers sit
32 papers from the last 6 months study NLRP3 inflammasome directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 30 preclinical · 2 unclassified
Themes 5 themes · 1 new direction
-
NLRP3-Linked Tissue Injury
Natural compounds and targeted probes are being used to restrain NLRP3-linked inflammation across kidney, nerve, brain, lung, eye, and liver injury. Recurrent mechanisms include Nrf2, SIRT1, NF-κB, HSP90, microglial polarization, pyroptosis, and Caspase-3 signaling. The work is moving from descriptive protection toward pathway-specific intervention, including a covalent LRR-domain probe and immunometabolic reprogramming. Organ protection and recovery remain the main endpoints rather than a single disease focus.
12 papers · 37.5%
-
NLRP3 Inhibitor Development
Direct NLRP3 blockade is being paired with plant extracts, traditional medicines, electroacupuncture, and metabolic interventions to reduce inflammatory injury. MCC950 remains the clearest pharmacologic benchmark, while Carabrone is positioned as a structure-directed inhibitor of Gln624/Ser658. Across studies, reduced Caspase-1 activation and IL-1β/IL-18 release are recurring endpoints, with neuroinflammation, stroke, gastric injury, and steatohepatitis as targets. Translation beyond preclinical models remains open.
8 papers · 25%
-
Neuroinflammation and Cognitive Decline
Microglial inflammation is emerging as a modifiable driver of cognitive impairment across diabetes, chemotherapy, surgery, hepatic encephalopathy, and aging. The interventions favor berberine, quercetin, thymol nanoparticles, Akkermansia muciniphila, and combination gut-directed therapy, often through Nrf2, HO-1, ER stress, or microglial polarization. NLRP3 suppression is repeatedly linked to improved hippocampal or behavioral outcomes and reduced hepatic injury. Genetic evidence complicates a simple inhibition model: NLRP3 haploinsufficiency can expose compensatory NLRP1-NLRP3 signaling during aging.
5 papers · 15.6%
-
NLRP3-Targeted Tissue Therapies
Anti-inflammatory treatment is shifting toward localized delivery and pathway-specific rescue, rather than systemic exposure alone. MCC950 is incorporated into silk microgel-hydrogel scaffolds, while a hydrogel patch delivers CRISPR editing to wounds. Small molecules such as p-coumaric acid and protocatechuic acid are used to regulate NLRP3 stability or fatty-acid-driven inflammation, alongside Salvia balansae phytochemical screening. The shared evidence is largely preclinical and spans nephropathy, wound repair, obesity-related inflammation, and tissue remodeling, leaving comparative efficacy unresolved.
5 papers · 15.6%
-
Oxidative Stress and NLRP3
NLRP3-driven oxidative stress is being examined as a shared mechanism in bone loss and neuroinflammation. Capsanthin is linked to osteoporosis protection through the Urotensin II receptor, while Theranekron is tested against lipopolysaccharide-induced neuroinflammation. Caspase-1 and related inflammasome activity recur as therapeutic readouts, but the disease settings and interventions remain distinct. The cluster supports a common inflammatory mechanism rather than a unified treatment direction.
2 papers · 6.2%
Partial NLRP3 loss can accelerate aging by inducing compensatory NLRP1 activity
NLRP3 haploinsufficiency in aging mice was assumed to model the beneficial partial inhibition sought therapeutically, but instead it produced late-life accelerated inflammatory aging associated with compensatory NLRP1 overexpression and an NLRP1–NLRP3 interaction. This gives NLRP3 a previously unrepresented homeostatic role in restraining compensatory inflammasome activity, indicating that partial pharmacological inhibition may have effects distinct from complete NLRP3 ablation and may require monitoring of NLRP1-dependent responses 42361162Jun.
Papers
The 32 papers from the last 6 months that study NLRP3 inflammasome directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
NLRP3-Linked Tissue Injury (12)
- Trilobatin attenuates allergic airway inflammation via multi-target suppression of NLRP3 inflammasome activation and caspase-3 signaling. Molecular biology reports · 25 Oct 2026 PMID 42927572
- Discovery of a Covalent NLRP3 LRR-Domain Probe: Reversing Renal Fibrosis via Immunometabolic Reprogramming in Organoid and Murine Models. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720495
- Aconitine promotes injured peripheral nerve recovery through restraining the activation of inflammasome-mediated cell pyroptosis and pathological inflammation. Experimental cell research · 21 Jul 2026 PMID 42480279
- Molecular mechanism of hydromorphone preconditioning in cerebral ischemia/reperfusion‑induced inflammatory injury. International journal of molecular medicine · 19 Jun 2026 PMID 42318970
- Irbesartan ameliorates high‑glucose‑induced epithelial‑mesenchymal transition by downregulating the expression of NLRP3 in HK‑2 cells. Molecular medicine reports · 19 Jun 2026 PMID 42318962
- Daphnetin alleviates neuropathic pain in rats by modulating spinal microglial polarization via the Nrf2/NLRP3 inflammasome pathway. International immunopharmacology · 17 Jun 2026 PMID 42308799
- Coordination-driven self-assembly of antioxidative and anti-inflammatory cerium-luteolin nanoparticles for effective treatment of ocular alkali burns. Journal of materials chemistry. B · 16 Jun 2026 PMID 42301120
- Aging reprograms microglia toward an inflammasome-linked response to traumatic brain injury. The Journal of clinical investigation · 15 Jun 2026 PMID 42294901
- Pt(IV) Complexes Incorporating CDC25A/NF-κB Dual Inhibitory 1,4-Naphthoquinone Derivatives Trigger Multimodal Cell Death in A2780 Ovarian Cancer Cells. Journal of medicinal chemistry · 11 Jun 2026 PMID 42275647
- Mechanism and Intervention of the NPY1R/CREB Signaling Axis in Regulating Inflammatory Response in Aged Ovarian Granulosa Cells and Ovarian Senescence. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 9 Jun 2026 PMID 42262763
- Disruption of upstream ox-LDL signaling and HSP90-mediated NLRP3 stability protects against experimental steatohepatitis. Naunyn-Schmiedeberg's archives of pharmacology · 25 May 2026 PMID 42183856
- Ginsenoside Rg3 potentiates cisplatin antitumor activity while mitigating nephrotoxicity through SIRT1‑mediated suppression of the NLRP3 inflammasome. International journal of molecular medicine · 22 May 2026 PMID 42169649
NLRP3 Inhibitor Development (8)
- Pyranocoumarin-enriched residue extracts of Angelica gigas suppress NLRP3 inflammasome activation and neuroinflammation. Molecular biology reports · 16 Oct 2026 PMID 42886278
- Potential Role of Zn Supplementation in Ameliorating Reserpine-Induced Fibromyalgia Manifestations Through Central NLRP3-Autophagy-Redox Network Modulation in Rats. Neurochemical research · 15 Oct 2026 PMID 42878974
- Targeting of NLRP3 Gln624/Ser658 by Carabrone attenuates inflammatory diseases. European journal of pharmacology · 4 Sept 2026 PMID 42697424
- Therapeutic Potential of NLRP3 Inhibitor MCC950 in Aging Mice Stroke Outcomes. Translational stroke research · 22 Aug 2026 PMID 42631814
- CD38 Inhibition Enhances FXR Signaling in Male Rats With Diabetic Steatohepatitis Through SIRT1-Dependent Suppression of NLRP3. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 4 Aug 2026 PMID 42550583
- Electroacupuncture alleviates spinal cord injury by regulating M2-like polarization of myeloid cells through CMPK2/NLRP3 inflammasome inhibition. International immunopharmacology · 7 Jun 2026 PMID 42251832
- Traditional herbal medicine Hyangsapyeongwi-san inhibits alcohol-induced gastric injury in mice by regulating NLRP3 inflammasome signaling. Journal of ethnopharmacology · 3 Jun 2026 PMID 42235716
- Melampodium divaricatum (Rich.) DC. extracts exert anti-inflammatory effects via inhibition of the NLRP3 inflammasome. Journal of ethnopharmacology · 27 May 2026 PMID 42202918
Neuroinflammation and Cognitive Decline (5)
- Berberine and lactulose combination therapy attenuates neuroinflammation and hepatic injury in thioacetamide-induced hepatic encephalopathy in rats. Metabolic brain disease · 19 Aug 2026 PMID 42616213
- NLRP3 haploinsufficiency unmasks a compensatory NLRP1-NLRP3 interaction that drives accelerated aging in mice. Science advances · 26 Jun 2026 PMID 42361162
- Akkermansia muciniphila alleviates diabetic cognitive impairment by inhibiting NLRP3 inflammasome activation and ameliorating hippocampal synaptic defects. Food & function · 16 Jun 2026 PMID 42300325
- Quercetin Alleviates Postoperative Cognitive Dysfunction of Aged Mice by Regulating Microglial Polarization through Inducing miR-379-5p RNA Modification. Molecular neurobiology · 28 May 2026 PMID 42209865
- Thymol nanoparticles ameliorate oxaliplatin-induced cognitive impairment via modulation of Nrf2/HO-1, endoplasmic reticulum stress, and NLRP3 inflammasome signaling in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 27 May 2026 PMID 42202464
NLRP3-Targeted Tissue Therapies (5)
- Integrative Phytochemical, Antioxidant, and NLRP3-Linked and Anti-Inflammatory Evaluation of Salvia balansae (Aurès Chemotype): Insights Into Its Safety and Therapeutic Potential. ChemistryOpen · 21 Aug 2026 PMID 42625396
- A surface-mediated hydrogel patch for localized CRISPR genome editing in inflammatory wound therapy. Materials horizons · 19 Aug 2026 PMID 42614060
- Targeting Cathepsin B with p-coumaric acid rescues WWP1-dependent proteasomal degradation of NLRP3 in hyperuricemic nephropathy. Molecular medicine (Cambridge, Mass.) · 26 Jun 2026 PMID 42363040
- MCC950-loaded silk microgel-hydrogel composite scaffolds effectively modulate inflammation for improving tissue interaction and remodeling. Acta biomaterialia · 4 Jun 2026 PMID 42242405
- Protocatechuic acid prevents obesity caused by long-chain saturated fatty acid-induced inflammation in mouse microglia via inhibition of the NF-κB pathway. PloS one · 1 Jun 2026 PMID 42224300
Oxidative Stress and NLRP3 (2)
- Capsanthin Attenuates Osteoporosis by Targeting the Urotensin II Receptor Pathway to Inhibit Oxidative Stress and NLRP3 Inflammasome Activation. Calcified tissue international · 6 Jul 2026 PMID 42410254
- Theranekron attenuates lipopolysaccharide-induced neuroinflammation via NLRP3 inflammasome modulation. Molecular biology reports · 26 May 2026 PMID 42189344
By study type
Preclinical: animal, cell and lab studies (30)
- Trilobatin attenuates allergic airway inflammation via multi-target suppression of NLRP3 inflammasome activation and caspase-3 signaling. Molecular biology reports · 25 Oct 2026 PMID 42927572
- Pyranocoumarin-enriched residue extracts of Angelica gigas suppress NLRP3 inflammasome activation and neuroinflammation. Molecular biology reports · 16 Oct 2026 PMID 42886278
- Potential Role of Zn Supplementation in Ameliorating Reserpine-Induced Fibromyalgia Manifestations Through Central NLRP3-Autophagy-Redox Network Modulation in Rats. Neurochemical research · 15 Oct 2026 PMID 42878974
- Discovery of a Covalent NLRP3 LRR-Domain Probe: Reversing Renal Fibrosis via Immunometabolic Reprogramming in Organoid and Murine Models. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720495
- Targeting of NLRP3 Gln624/Ser658 by Carabrone attenuates inflammatory diseases. European journal of pharmacology · 4 Sept 2026 PMID 42697424
- Therapeutic Potential of NLRP3 Inhibitor MCC950 in Aging Mice Stroke Outcomes. Translational stroke research · 22 Aug 2026 PMID 42631814
- Integrative Phytochemical, Antioxidant, and NLRP3-Linked and Anti-Inflammatory Evaluation of Salvia balansae (Aurès Chemotype): Insights Into Its Safety and Therapeutic Potential. ChemistryOpen · 21 Aug 2026 PMID 42625396
- Berberine and lactulose combination therapy attenuates neuroinflammation and hepatic injury in thioacetamide-induced hepatic encephalopathy in rats. Metabolic brain disease · 19 Aug 2026 PMID 42616213
- A surface-mediated hydrogel patch for localized CRISPR genome editing in inflammatory wound therapy. Materials horizons · 19 Aug 2026 PMID 42614060
- CD38 Inhibition Enhances FXR Signaling in Male Rats With Diabetic Steatohepatitis Through SIRT1-Dependent Suppression of NLRP3. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 4 Aug 2026 PMID 42550583
- Aconitine promotes injured peripheral nerve recovery through restraining the activation of inflammasome-mediated cell pyroptosis and pathological inflammation. Experimental cell research · 21 Jul 2026 PMID 42480279
- Capsanthin Attenuates Osteoporosis by Targeting the Urotensin II Receptor Pathway to Inhibit Oxidative Stress and NLRP3 Inflammasome Activation. Calcified tissue international · 6 Jul 2026 PMID 42410254
- NLRP3 haploinsufficiency unmasks a compensatory NLRP1-NLRP3 interaction that drives accelerated aging in mice. Science advances · 26 Jun 2026 PMID 42361162
- Molecular mechanism of hydromorphone preconditioning in cerebral ischemia/reperfusion‑induced inflammatory injury. International journal of molecular medicine · 19 Jun 2026 PMID 42318970
- Irbesartan ameliorates high‑glucose‑induced epithelial‑mesenchymal transition by downregulating the expression of NLRP3 in HK‑2 cells. Molecular medicine reports · 19 Jun 2026 PMID 42318962
- Daphnetin alleviates neuropathic pain in rats by modulating spinal microglial polarization via the Nrf2/NLRP3 inflammasome pathway. International immunopharmacology · 17 Jun 2026 PMID 42308799
- Coordination-driven self-assembly of antioxidative and anti-inflammatory cerium-luteolin nanoparticles for effective treatment of ocular alkali burns. Journal of materials chemistry. B · 16 Jun 2026 PMID 42301120
- Akkermansia muciniphila alleviates diabetic cognitive impairment by inhibiting NLRP3 inflammasome activation and ameliorating hippocampal synaptic defects. Food & function · 16 Jun 2026 PMID 42300325
- Aging reprograms microglia toward an inflammasome-linked response to traumatic brain injury. The Journal of clinical investigation · 15 Jun 2026 PMID 42294901
- Pt(IV) Complexes Incorporating CDC25A/NF-κB Dual Inhibitory 1,4-Naphthoquinone Derivatives Trigger Multimodal Cell Death in A2780 Ovarian Cancer Cells. Journal of medicinal chemistry · 11 Jun 2026 PMID 42275647
- Mechanism and Intervention of the NPY1R/CREB Signaling Axis in Regulating Inflammatory Response in Aged Ovarian Granulosa Cells and Ovarian Senescence. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 9 Jun 2026 PMID 42262763
- Electroacupuncture alleviates spinal cord injury by regulating M2-like polarization of myeloid cells through CMPK2/NLRP3 inflammasome inhibition. International immunopharmacology · 7 Jun 2026 PMID 42251832
- MCC950-loaded silk microgel-hydrogel composite scaffolds effectively modulate inflammation for improving tissue interaction and remodeling. Acta biomaterialia · 4 Jun 2026 PMID 42242405
- Traditional herbal medicine Hyangsapyeongwi-san inhibits alcohol-induced gastric injury in mice by regulating NLRP3 inflammasome signaling. Journal of ethnopharmacology · 3 Jun 2026 PMID 42235716
- Protocatechuic acid prevents obesity caused by long-chain saturated fatty acid-induced inflammation in mouse microglia via inhibition of the NF-κB pathway. PloS one · 1 Jun 2026 PMID 42224300
- Quercetin Alleviates Postoperative Cognitive Dysfunction of Aged Mice by Regulating Microglial Polarization through Inducing miR-379-5p RNA Modification. Molecular neurobiology · 28 May 2026 PMID 42209865
- Melampodium divaricatum (Rich.) DC. extracts exert anti-inflammatory effects via inhibition of the NLRP3 inflammasome. Journal of ethnopharmacology · 27 May 2026 PMID 42202918
- Thymol nanoparticles ameliorate oxaliplatin-induced cognitive impairment via modulation of Nrf2/HO-1, endoplasmic reticulum stress, and NLRP3 inflammasome signaling in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 27 May 2026 PMID 42202464
- Theranekron attenuates lipopolysaccharide-induced neuroinflammation via NLRP3 inflammasome modulation. Molecular biology reports · 26 May 2026 PMID 42189344
- Ginsenoside Rg3 potentiates cisplatin antitumor activity while mitigating nephrotoxicity through SIRT1‑mediated suppression of the NLRP3 inflammasome. International journal of molecular medicine · 22 May 2026 PMID 42169649
Unclassified: not yet indexed with MeSH (2)
- Targeting Cathepsin B with p-coumaric acid rescues WWP1-dependent proteasomal degradation of NLRP3 in hyperuricemic nephropathy. Molecular medicine (Cambridge, Mass.) · 26 Jun 2026 PMID 42363040
- Disruption of upstream ox-LDL signaling and HSP90-mediated NLRP3 stability protects against experimental steatohepatitis. Naunyn-Schmiedeberg's archives of pharmacology · 25 May 2026 PMID 42183856
Written from 32 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-12 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.